Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
754.10
+4.77 (+0.64%)
Streaming Delayed Price
Updated: 1:13 PM EST, Jan 22, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
59
60
Next >
23andMe’s $305M Sale To Co-Founder Wojcicki Approved: California Loses Legal Battle Over DNA Privacy
↗
July 07, 2025
A U.S. bankruptcy judge ruled that California's appeal to block the deal was unlikely to succeed, rejecting claims that the sale violated state genetic privacy laws.
Via
Stocktwits
Topics
Bankruptcy
Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot
↗
July 07, 2025
Apogee Therapeutics shares crumbled Monday despite promising results for what could become a twice-yearly eczema shot.
Via
Investor's Business Daily
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
July 07, 2025
Via
Investor Brand Network
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
July 07, 2025
EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:REGN),(NASDAQ:VRTX),(OTCQX:RHHBY),(NYSE:MRK) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
2 Beaten-Down Stocks to Buy and Hold
↗
July 05, 2025
Via
The Motley Fool
Topics
Death
REGENERON PHARMACEUTICALS (NASDAQ:REGN) - A Potential Undervalued Biotech Stock
↗
July 04, 2025
REGENERON PHARMACEUTICALS (NASDAQ:REGN) offers strong profitability, financial health, and an attractive valuation, making it a potential pick for value investors in the biotech sector.
Via
Chartmill
Regeneron's Lynozyfic Gains Accelerated FDA Approval For Heavily Pre-Treated Multiple Myeloma
↗
July 03, 2025
FDA grants accelerated approval to Regeneron's Lynozyfic for relapsed multiple myeloma after strong results in a Phase 1/2 trial.
Via
Benzinga
Regeneron’s Therapy For Blood Cancer Bags FDA Approval: REGN Stock Jumps
↗
July 02, 2025
While Lynozyfic was granted accelerated approval based on response rate in the LINKER-MM1 trial, continued approval may depend upon verification and description of clinical benefit in a confirmatory...
Via
Stocktwits
Topics
Death
Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma
July 02, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today
↗
July 01, 2025
Via
Benzinga
Regeneron Pharmaceuticals Unusual Options Activity For July 01
↗
July 01, 2025
Via
Benzinga
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
June 28, 2025
Nektar Therapeutics soared 157% after Rezpeg succeeded in a Phase 2b eczema trial. Analysts forecast huge upside—here’s why there could be more gains ahead.
Via
MarketBeat
Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025
June 26, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
1 Profitable Stock for Long-Term Investors and 2 to Question
June 26, 2025
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...
Via
StockStory
Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?
↗
June 25, 2025
Nektar's rezpegaldesleukin met key efficacy targets in a mid-stage eczema study, though analysts flagged safety and differentiation concerns.
Via
Benzinga
Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization
June 24, 2025
Initiative aims to expand and encourage philanthropy to help patients with retinal diseases afford their medications
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks
June 22, 2025
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Regeneron (NASDAQ:REGN) and its peers.
Via
StockStory
Topics
Artificial Intelligence
$100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
↗
June 20, 2025
Via
Benzinga
FDA Approves Regeneron Sanofi Treatment For Rare Autoimmune Skin Disorder
↗
June 20, 2025
Dupixent approved by FDA for bullous pemphigoid, offering a new option for adults with the rare autoimmune skin disease following positive trial results.
Via
Benzinga
Regeneron, Sanofi Say Their Inflammation Drug Approved By FDA For Rare Skin Disease Affecting Elderly, But Retail Stays Dull
↗
June 20, 2025
The injection is now approved in the U.S. to treat eight distinct diseases with underlying type 2 inflammation.
Via
Stocktwits
Topics
Supply Chain
Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)
June 20, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Scholar Rock Stock Soars After Investigational Drug Helps Preserve Lean Mass: Retail Flags Lack Of Incremental Weight Loss
↗
June 18, 2025
Apitegromab therapy with Tirzepatide preserved an additional 4.2 pounds of lean mass compared to Tirzepatide alone in the study, the company said.
Via
Stocktwits
Topics
Death
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study
↗
June 18, 2025
Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body composition in Phase 2 trial.
Via
Benzinga
Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
June 15, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
These Were the 2 Worst-Performing Stocks in the S&P 500 in May 2025
↗
June 15, 2025
These two S&P 500 stocks, which fell between 18.2% and 26.6% in May, are worth watching.
Via
The Motley Fool
Topics
Stocks
23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process
June 13, 2025
From
23andMe, Inc.
Via
GlobeNewswire
These Were the 2 Worst-Performing Stocks in the Nasdaq-100 in May 2025
↗
June 13, 2025
Think every Nasdaq-100 stock was a winner last month? The numbers might surprise you.
Via
The Motley Fool
Is This Stock a Buy After Acquiring a Potential Zepbound Competitor?
↗
June 12, 2025
Via
The Motley Fool
Novo Nordisk, Deep Apple Launch Drug Discovery Alliance For Weight Loss Oral Therapies
↗
June 11, 2025
Novo Nordisk and Deep Apple ink a deal to develop oral therapies targeting a novel GPCR for cardiometabolic diseases, including obesity.
Via
Benzinga
Regeneron Pharma Shares Rise Over 3% After Key Signal
↗
June 10, 2025
A significant trading signal occurred for Regeneron Pharma stock at a price of $501.83, after which REGN rose up to 3.2%.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
59
60
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
